Presentation is loading. Please wait.

Presentation is loading. Please wait.

Shalev V, et al. Arch Intern Med 2009; 169:260-268.

Published byBrendan Davidson Modified over 9 years ago

Similar presentations

Presentation on theme: "Shalev V, et al. Arch Intern Med 2009; 169:260-268."— Presentation transcript:

1 Shalev V, et al. Arch Intern Med 2009; 169:260-268

2 Characteristics of Adults Initiating a New Treatment With a Statin Agent, Maccabi Healthcare Services, Israel, 1998-2006 – Part I Shalev V, et al. Arch Intern Med 2009; 169:260-268

3 Characteristics of Adults Initiating a New Treatment With a Statin Agent, Maccabi Healthcare Services, Israel, 1998-2006 – Part II

4 Shalev V, et al. Arch Intern Med 2009; 169:260-268 Association Between Potential Determinants and All-Cause Mortality, Maccabi Healthcare Services, Israel, 1998-2006

5 Shalev V, et al. Arch Intern Med 2009; 169:260-268 Proportional effects of continuation of statins on reduction in all-cause mortality per 10% proportion of days covered with statins in primary prevention (A) and secondary prevention (B) cohorts

6 Shalev V, et al. Arch Intern Med 2009; 169:260-268 Proportion of Days Covered With Statins and All-Cause Mortality, Maccabi Healthcare Services, Israel, 1998-2006

7 Shalev V, et al. Arch Intern Med 2009; 169:260-268 Hazard ratios and 95% confidence intervals of all-cause mortality according to proportion of days covered with statins in primary prevention (A) and secondary prevention (B) cohorts, Maccabi Healthcare Services, Israel, 1998-2006

Download ppt "Shalev V, et al. Arch Intern Med 2009; 169:260-268."

Similar presentations

Things we knew, things we did… Things we have learnt, things we should do LIPID MANAGEMENT IN PRIMARY CARE: HOW WELL DO WE DO? Dr. Carlos Brotons Research.

Things we knew, things we did… Things we have learnt, things we should do LIPID MANAGEMENT IN PRIMARY CARE: HOW WELL DO WE DO? Dr. Carlos Brotons Research.
Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165: 2264-2271.

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
analysis from the SHIFT study

analysis from the SHIFT study
Www.aodhealth.org1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Weng TC, et al. J Clin Pharm Ther 2010;35:
Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.

Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.
VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366:1279-89. Charbonnel B et al. Diabetes Care. 2004;27:1647-53. Objective: Assess the effects.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.
Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:2184- 92.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:
Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”

Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”
Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;388-393.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;
The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.

The combined influence of leisure-time physical activity and weekly alcohol intake on fatal ischaemic heart disease and all-cause mortality by Jane Østergaard.
Hsia J et al. J Am Coll Cardiol 2011;57:1666-75. Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:1666-75.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Similar presentations

Ads by Google